PRRT2 and myotonic dystrophy type 1: In transgenic mouse models of DM1, mice treated with specific inhibitors of the PKC pathway showed amelioration of cardiac abnormalities associated with the disease phenotype, presumably by limiting CELF1 phosphorylation [75].